SCOPUS 정보 검색 플랫폼

Volumn 33, Issue 4, 2010, Pages 730-732

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

(7) Ahrén, Bo a Foley, James E b Ferrannini, Ele c Matthews, David R d Zinman, Bernard e Dejager, Sylvie f Fonseca, Vivian A g

a LUND UNIVERSITY (Sweden)

b NOVARTIS PHARMA AG (Switzerland)

c UNIVERSITY OF PISA (Italy)

d CHURCHILL HOSPITAL (United Kingdom)

e MOUNT SINAI HOSPITAL (Canada)

f NOVARTIS PHARMA K K (Japan)

g TULANE UNIVERSITY HEALTH SCIENCES CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; VILDAGLIPTIN;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTICLE; DRUG EFFECT; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; POSTPRANDIAL STATE;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NITRILES; POSTPRANDIAL PERIOD; PYRROLIDINES; SULFONYLUREA COMPOUNDS;

EID: 77953055922 PISSN: 01495992 EISSN: 19355548 Source Type: Journal
DOI: 10.2337/dc09-1867 Document Type: Article

Times cited : (74)

References (11)

1
- 34147189738
- The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
- Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92: 1249-1255
- (2007) J Clin Endocrinol Metab , vol.92 , pp. 1249-1255
- Balas, B.¹ Baig, M.R.² Watson, C.³ Dunning, B.E.⁴ Ligueros-Saylan, M.⁵ Wang, Y.⁶ He, Y.L.⁷ Darland, C.⁸ Holst, J.J.⁹ Deacon, C.F.¹⁰ Cusi, K.¹¹ Mari, A.¹² Foley, J.E.¹³ DeFronzo, R.A.¹⁴

2
- 2442482515
- Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
- Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-2084
- (2004) J Clin Endocrinol Metab , vol.89 , pp. 2078-2084
- Ahrén, B.¹ Landin-Olsson, M.² Jansson, P.A.³ Svensson, M.⁴ Holmes, D.⁵ Schweizer, A.⁶

3
- 38949195291
- The islet enhancer vildagliptin: Mechanisms of improved glucose metabolism
- Ahrén B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl 2008;159:8-14
- (2008) Int J Clin Pract Suppl , vol.159 , pp. 8-14
- Ahrén, B.¹ Foley, J.E.²

4
- 58149330590
- Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-166
- (2009) Diabetes Obes Metab , vol.11 , pp. 157-166
- Ferrannini, E.¹ Fonseca, V.² Zinman, B.³ Matthews, D.⁴ Ahrén, B.⁵ Byiers, S.⁶ Shao, Q.⁷ Dejager, S.⁸

5
- 52249090472
- Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: Analysis of pooled vildagliptin monotherapy database
- Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008;10:931-938
- (2008) Diabetes Obes Metab , vol.10 , pp. 931-938
- Pratley, R.E.¹ Schweizer, A.² Rosenstock, J.³ Foley, J.E.⁴ Banerji, M.A.⁵ Pi-Sunyer, F.X.⁶ Mills, D.⁷ Dejager, S.⁸

6
- 38149096290
- Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
- Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008;31:30-35
- (2008) Diabetes Care , vol.31 , pp. 30-35
- Rosenstock, J.¹ Foley, J.E.² Rendell, M.³ Landin-Olsson, M.⁴ Holst, J.J.⁵ Deacon, C.F.⁶ Rochotte, E.⁷ Baron, M.A.⁸

7
- 38149110484
- The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucose
- Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE. The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes 2008;31: 108-113
- (2008) Diabetes , vol.31 , pp. 108-113
- Utzschneider, K.M.¹ Tong, J.² Montgomery, B.³ Udayasankar, J.⁴ Gerchman, F.⁵ Marcovina, S.M.⁶ Watson, C.E.⁷ Ligueros-Saylan, M.A.⁸ Foley, J.E.⁹ Holst, J.J.¹⁰ Deacon, C.F.¹¹ Kahn, S.E.¹²

8
- 54049099230
- Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes
- Foley JE, Ligueros-Saylan M, He YL, Holst JJ, Deacon CF, Dunning BE, Leone-Jones A, Yu T, Kelley DE. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 2008;40:727-730
- (2008) Horm Metab Res , vol.40 , pp. 727-730
- Foley, J.E.¹ Ligueros-Saylan, M.² He, Y.L.³ Holst, J.J.⁴ Deacon, C.F.⁵ Dunning, B.E.⁶ Leone-Jones, A.⁷ Yu, T.⁸ Kelley, D.E.⁹

9
- 65249095686
- Vildagliptin enhances islet responsiveness to both hyper- And hypoglycemia in patients with type 2 diabetes
- Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-1243
- (2009) J Clin Endocrinol Metab , vol.94 , pp. 1236-1243
- Ahrén, B.¹ Schweizer, A.² Dejager, S.³ Dunning, B.E.⁴ Nilsson, P.M.⁵ Persson, M.⁶ Foley, J.E.⁷

10
- 33847021177
- Sulphonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1
- de Heer J, Holst JJ. Sulphonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56:438-443
- (2007) Diabetes , vol.56 , pp. 438-443
- De Heer, J.¹ Holst, J.J.²

11
- 38149137991
- Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia
- Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE. Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008;93: 103-109
- (2008) J Clin Endocrinol Metab , vol.93 , pp. 103-109
- Mari, A.¹ Scherbaum, W.A.² Nilsson, P.M.³ Lalanne, G.⁴ Schweizer, A.⁵ Dunning, B.E.⁶ Jauffret, S.⁷ Foley, J.E.⁸

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.